Business Context and Reporting Period
Company: Incyte Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1997
Business Overview: Incyte is a provider of genomic information and services to the biotechnology, pharmaceutical, and agricultural industries. Its primary business model involves licensing access to proprietary genomic databases (LifeSeq, PathoSeq, ZooSeq) and bioinformatics software to collaborators. Revenue is derived primarily from database access fees, with potential future income from milestone payments and royalties on products developed using Incyte's data.
Key Financial Metrics
| Metric (in thousands) | 1997 | 1996 | 1995 |
|---|---|---|---|
| Revenues | $88,351 | $41,785 | $12,212 |
| Net Income (Loss) | $10,408 | $(6,761) | $(9,937) |
| Operating Income (Loss) | $7,290 | $(9,036) | $(10,927) |
| Research & Development Expenses | $68,927 | $40,864 | $19,212 |
| Cash, Cash Equivalents & Securities | $114,666 | $38,250 | $41,181 |
| Working Capital | $91,523 | $22,047 | $38,983 |
| Accumulated Deficit | $(26,114) | $(36,522) | $(29,761) |
Per Share Data (1997): Basic Net Income of $0.47; Diluted Net Income of $0.43.
Liquidity: The company generated $18.7 million in net cash from operating activities in 1997. Capital expenditures were $26.1 million.
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported its first annual net income of $10.4 million in 1997, reversing a net loss of $6.8 million in 1996. This was driven by a 111% increase in revenue and improved operating leverage.
- Revenue Growth: Revenues more than doubled from $41.8 million in 1996 to $88.4 million in 1997, primarily due to an increase in the number of database collaboration agreements (19 collaborators as of Dec 31, 1997, compared to 10 in 1996).
- Customer Concentration: Customer concentration decreased significantly. In 1996, three customers accounted for over 10% of revenue each. In 1997, no single customer contributed more than 10% of total revenues.
- Capital Structure: Cash and marketable securities increased from $38.3 million to $114.7 million, largely due to $87.2 million in net proceeds from a follow-on public stock offering in August 1997.
- Acquisitions: The company completed the acquisition of Synteni, Inc. in January 1998 (subsequent to the reporting period), which will be accounted for as a pooling of interests in 1998.
Outlook, Risks, and Contingencies
- Guidance & Outlook: Management expects continued investment in R&D, marketing, and sales in 1998. Earnings per share and growth rates are expected to decrease in the first half of 1998 due to the incorporation of Synteni's operating losses. The company believes current cash resources are adequate through 1998.
- Legal Contingency: On January 6, 1998, Affymetrix, Inc. filed a lawsuit alleging patent infringement by Incyte and Synteni regarding high-density arrays. Affymetrix seeks a permanent injunction and trebled damages. Incyte intends to defend vigorously, but litigation could result in substantial expenses.
- Patent Risks: The company faces uncertainty regarding the patentability of partial gene sequences and the potential for interference proceedings. Public availability of gene sequences by competitors (e.g., Merck, TIGR) may reduce the value of Incyte's proprietary databases.
- Operational Risks: The business relies heavily on the pharmaceutical industry's R&D spending. The company has a history of operating losses and an accumulated deficit of $26.1 million. Future profitability depends on retaining existing collaborators and signing new ones.
- Joint Venture: Incyte holds a 50% interest in diaDexus LLC (with SmithKline Beecham), which incurred losses in 1997. The company expects these losses to increase in 1998 as operations expand.
Investor Verification Checklist
- Revenue Sustainability: Verify the renewal rates of the 19 existing database collaboration agreements, as they typically have three-year terms and are critical to future revenue.
- Legal Exposure: Monitor the status of the Affymetrix patent infringement lawsuit filed in January 1998 and potential financial impact.
- Acquisition Integration: Assess the financial impact of the Synteni acquisition on 1998 earnings, specifically the dilution effect and integration costs.
- R&D Efficiency: Evaluate the return on the $68.9 million R&D spend, particularly regarding the development of new database modules and the commercialization of the diaDexus joint venture.
- Patent Portfolio: Review the status of pending patent applications for partial gene sequences, given the uncertainty in USPTO guidelines and potential for abandonment.